NCT05691010RecruitingPhase 1
A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer
Memorial Sloan Kettering Cancer Center7 sites in 1 country28 target enrollmentStarted: January 10, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 28
- Locations
- 7
- Primary Endpoint
- Feasibility of integrated delivery of short-course IMRT with carboplatin/paclitaxel in patients with stage III endometrial cancer
Study Overview
Brief Summary
The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must have newly diagnosed endometrial carcinoma. The following histologic subtypes are eligible for inclusion: endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma.
- •Surgery must have included a hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node surgical assessment (sentinel lymph node mapping and/or sampling). Para-aortic lymph node surgical assessment is optional.
- •Patients must have FIGO (2009) stage IIIA or IIIC1 disease (as determined by surgical staging).
- •Patients must consent to testing with MSK-IMPACT part A and are encouraged to consent to both parts A and C.
- •Age ≥ 18 years.
- •Patients must have an Karnofsky Performance Status (KPS) ≥ 70 (or ECOG 0 or 1).
- •Neurologic function: Neuropathy (sensory and motor) grade ≤
- •No residual gross disease after surgery.
- •No prior radiation therapy or chemotherapy for treatment of endometrial cancer.
- •No active infection requiring antibiotics, except for uncomplicated urinary tract infection.
- •Patients must have adequate organ function, defined by the following laboratory results prior to first study treatment:
- •Absolute neutrophil count (ANC) ≥ 1500/mcL
- •Platelet count ≥ 100,000/mcL
- •AST/ALT ≤ 3X upper limit of normal (ULN)
- •Total bilirubin ≤ 1.5X ULN. Patients with known Gilbert's disease and a total bilirubin ≤ 3X ULN may be enrolled.
- •Creatinine ≤ 1.5X ULN
- •Entry into study is limited to no more than 12 weeks from the date of surgery.
- •Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- •Patients of childbearing age will by definition have undergone hysterectomy and bilateral oophorectomy prior to study enrollment.
- •Participants must agree not to breastfeed during the study or for 150 days after the last dose of study treatment.
Exclusion Criteria
- •Patients whose endometrial cancers harbor known pathogenic POLE mutations
- •Patients whose endometrial cancers are mismatch repair deficient, as determined by immunohistochemical staining for MLH1, PMS2, MSH2, and MSH6 and/or MSI-H
- •Active inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
- •History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. This includes but is not limited to: uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, and superior vena cava syndrome.
- •Patients unfit for pelvic radiation therapy due to the following:
- •Has had radiation therapy encompassing >20% of the bone marrow within 2 weeks, or any radiation therapy within 1 week prior to day 1 of protocol therapy
- •Patients with a history of pelvic radiation.
- •Patients with a history or current diagnosis of a vesicovaginal, enterovaginal, or colovaginal fistula.
- •Any hematological abnormality or disorder that would be a contraindication to radiation per the treating physician.
Arms & Interventions
Participants with Endometrial Cancer
Experimental
Participants have stage III endometrial cancer
Intervention: Intensity-modulated radiation therapy (Radiation)
Participants with Endometrial Cancer
Experimental
Participants have stage III endometrial cancer
Intervention: Paclitaxel (Drug)
Participants with Endometrial Cancer
Experimental
Participants have stage III endometrial cancer
Intervention: Carboplatin (Drug)
Outcomes
Primary Outcomes
Feasibility of integrated delivery of short-course IMRT with carboplatin/paclitaxel in patients with stage III endometrial cancer
Time Frame: up to 3 years
Feasibility of study treatment is defined as defined as the number of participants who complete all 6 planned cycles of carboplatin and paclitaxel with no delays in chemotherapy cycles greater than 21 days.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (7)
Loading locations...
Similar Trials
Terminated
Phase 1
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With DurvalumabCarcinoma, Non-Small Cell LungLung CancerNCT04748419University of Nebraska6
Unknown
Phase 1
Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate CancerProstate CancerNCT01505075Sunnybrook Health Sciences Centre30
Completed
Phase 1
Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate CancerProstate CancerNCT01146340Sunnybrook Health Sciences Centre30
Completed
Phase 1
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersNon Small Cell Lung Cancer (NSCLC)MetastaticBreast CancerPancreatic CancerMelanomaNCT02639026Abramson Cancer Center at Penn Medicine53
Unknown
Not Applicable
Hypofractionated Radiotherapy and Concurrent Cisplatin for Head and Neck CancerComplications RadiotherapyNCT03194061Barretos Cancer Hospital20